In the present study, the effects of an intracerebroventricular (i.c.v.) dose of histamine (0.1, 1.0 or 10.0 /xg) on the hippocampal somatostatin (SS) receptor/effector system in Wistar rats were investigated. In view of the rapid onset of histamine action, the effects of histamine on the somatostatinergic system were studied 2 h after its administration. Hippocampal SS-like immunoreactivity (SSLI) levels were not modified by any of the histamine doses studied. SS-mediated inhibition of basal and forskolin (FK)-stimulated adenylyi cyclase (AC) activity was markedly increased in hippocampal membranes from rats treated with 10 tzg of histamine (23% + 1% vs. 17% + 1% and 37% -i-2% vs. 23% + 1%, respectively). In contrast, neither the basal nor the FK-stimulated enzyme activities were affected by histamine administration. The functional activity of the hippocampal guanine-nucleotide binding inhibitory protein (G i protein), as assessed by the capacity of the stable GTP analogue 5'-guanylylimidodiphosphate (Gpp{NH]p) to inhibit FK-stimulated AC activity, was not modified by histamine administration. These data suggest that the increased response of the enzyme to SS was not related to an increased functional activity of G i proteins. In fact, the increased AC response to SS in hiPpocampal membranes from histamine (10 /zg)-treated rats was associated with quantitative changes in the SS receptors. Equilibrium binding data obtained with [12~I]Tyr~-SS indicate an increase in the number of specific SS receptors (541 + 24 vs. 365 + 16 fmol/mg protein, P < 0.001) together with a decrease in their apparent affinity (0.57 + 0.04 vs. 0.41 + 0.03 nM, P < 0.05) in rat hippocampai membranes from histamine (10 /xg)-treated rats as compared to control animals. With the aim of determining if these changes were related to histamine binding to its specific receptor sites, the histaminergic H1 and H 2 receptor antagonists mepyramine and cimetidine, respectively, were administered 1 h before histamine injection. The pretreatment with mepyramine or cimetidine induced an increase in the number and affinity constant of the SS receptors whereas the simultaneous pretreatment with both histamine antagonists prevented the histamine-induced changes in SS binding to its receptors. Since the hippocampal SS receptor/effector system is modulated by histamine, it is tempting to speculate that in the hippocampus, SS could be involved as a mediator of the histamine effects on behaviors such as learning and memory.
Introduction
Somatostatin (SS) is a neuropeptide widely distributed in the brain [11] . In the hippocampus, immunohistochemical studies have revealed many SS-containing interneurons and a profuse network of intrinsic and extrinsic SS-containing fibers that appear to project to pyramidal and granule neurons [3, 18] . Specific SS receptors are present in the hippocampus [39] , suggesting that SS may be a neurotransmitter or neuromodulator in this brain area. Biochemical analysis demonstrated that SS receptors are coupled to GTP-binding proteins (G-proteins) [22] . The G-proteins then couple the SS receptors with multiple effector proteins to either inhibit them, as occurs with adenylyl cyclase (AC) [44] and voltage-dependent Ca 2÷ channels [52] , or to activate them, as occurs with different K ÷ channels [51] . Several findings suggest an important role for SS in cognitive processes such as learning and memory by modulating neuronal activity in the hippocampus [2, 16] . Recently, it has been shown that SMS 201-995, a specific peptidase-resistant SS analog, has anticonvulsant activity on EEG seizures induced by glutamate analogs in the hippocampus [50] , thus suggesting an inhibitory role of hippocampal SS on seizures.
There are data supporting the hypothesis that the so-matostatinergic and histaminergic systems are interrelated and that reciprocal regulation occurs. Centrally administered SS produces a dose-related decrease in histamine levels in the rat hippocampus [7] . Ample evidence exists for histaminergic projections to the hippocampus [33, 53] , a brain area rich in SS content and receptors [21, 40] . These and other subcortical afferents could play a decisive role in the expression of long-term potentiation. Furthermore, several studies suggest that the histamine H 1 and H 2 receptors may mediate together the actions of histamine in the hippocampus [46] . SS and histamine participate in a similar manner in the regulation of a number of behaviors, including those subserving memory and learning [2, 16, 19, 46, 49] and motor activity [11, 46] . It has been suggested that SS [24] and histamine [43] may act as endogenous anticonvulsants in the hippocampus. In view of all the above, the aim of this study was to elucidate the role of histamine in modulating the SS receptor/cffector system in the rat hippocampus. Since it appears that SS modulation of neuronal function involves the inhibition of AC activity by the occupation of receptor sites negatively coupled, via G-proteins, to this enzyme [32] , we have assessed the integrity of SS receptor function by assaying both the levels of receptor recognition sites and the ability of SS to inhibit AC activity. In addition, we assessed the functional activity of the guanine nucleotide-binding inhibitory protein (G~) and determined the effect of histamine on SS-like immunoreactivity (SSLI) content in the hippocampus. The effects of pretreatment with the histamine H~ and H 2 receptor antagonists mepyramine and cimetidine, respectively, on the above-cited parameters were also evaluated.
C-terminal cysteine residue is required for antibody binding, suggesting that the antigen site is directed towards the central part of the molecule containing the tryptophan residue. The binding of SS-14 to this antibody does not depend on an intact disulfide bond in the molecule as breaking of the disulfide bond by reaction with (I. 1% mercaptoethanol (boiling water bath, 5 min) did not change the immunoreactivity of the peptide.
Experimental animals
The animals used in this study were Wistar rats ( n = 6(1) weighing between 200 and 250 g. Rats were maintained on a 12 h light/dark cycle (07.00-19.00) and allowed free access to food. Histamine was dissolved in 0.9% NaCl and administered intracerebroventricularly (i.c.v.) in a volume of l0/zl according to the method described by Noble et al. [27] at a dose of 0.1, 1.0 or 10.0 /xg of free base, as previously described [41] . Mepyramine (30 mg/kg) [28] was dissolved in saline and cimetidinc (20 p,g/rat) [26] was first dissolved in dimethyl sulfoxide and then diluted with saline to the concentration required. Mepyramine and/or cimetidine were administered via an intraperitoneal (i.p.) and i.c.v, injection, respectively, 1 h before histamine administration. In all experiments, control animals received equivalent volumes of the corresponding vehicle. Rats were killed by decapitation 2 h after the last drug injection. The brain was rapidly removed and the hippocampus was dissected over ice according to the method of Glowinski and Iversen [14].
Tissue extraction and SS radioimmunoassay

Materials and methods
Chemicals
Synthetic Tyrt~-SS and SS-14 were purchased from Universal Biologicals Ltd (Cambridge, U.K.): carrier-free Na12Sl (IMS 30. 100 mCi/ml) and rabbit antibody were purchased from the Radiochemical (?entre (Amersham, UK); histamine hydrochloride, mepyramine maleate, cimetidine, bacitracin, bovine serum albumin (BSA), forskolin (FK), phenylmethylsulfonyl fluoride (PMSF), 3-isobutyl-1-methylxanthine (IBMX), GTP and Gpp[NH]p were supplied by Sigma Quimica (Madrid, Spain). The rabbit antibody used in the radioimmunoassay technique was purchased from the Radiochemical Centre (Amersham, UK). This antiserum was raised in rabbits against SS-14 conjugated to BSA and is specific for SS, but since SS-14 constitutes the C-terminal portions of both SS-25 and SS-28, the antiserum does not distinguish between these three forms. Cross-reactivity with other peptides was less than 0.5%. Cross-reaction with several SS analogues demonstrated that neither the N-terminal glycine nor the For SSLI measurements, the hippocampus was rapidly homogenized in 1 ml 2 M acetic acid using a Brinkman polytron (setting 5, 30 s). The extracts were boiled for 5 min in a water bath, chilled in ice, and aliquots (100 /a,l) were removed for protein determination [34] . The homogenates were subsequently centrifuged at 15000 × g for 15 min at 4°C and the supernatant was neutralized with 2 M NaOH. The extracts were then stored at -70°C until assay. The SSLI content was determined in tissue extracts by a modified radioimmunoassay method [34] , with a sensitivity limit of 10 pg/ml. Incubation tubes prepared in duplicate contained 1011 p,I samples of unknown or standard solutions of 0-500 pg cyclic SS tetradecapeptide diluted in phosphate buffer (0.05 M, pH 7.2 containing I).3% BSA, 0.01 M EDTA), 200 /xl of appropriately diluted anti-SS serum, 100 /xl of freshly prepared [Iz~I]Tyr11-SS diluted in buffer to give 6000 cpm/assay tube (equivalent to 5-10 pg), and enough buffer to give a final volume of 0.8 ml. All reagents, as well as the assay tubes, were kept chilled in ice before their incubation for 48 h at 4°C. Separation of bound and free hormone was accomplished by the addition of 1 ml dextran-coated charcoal (dextran T-70: (I.2% w/v, Pharmacia, Uppsala, Swe-den; charcoal Norit A: 2% w/v, Serva Feinbiochemica, Heidelberg, Germany). Serial dilution curves for the hippocampus were parallel to the standard curve. The intraand inter-assay variation coefficients were 6.2 and 8.6%, respectively.
Binding assay
Tyr1~-SS was radioiodinated by chloramine-T iodination according to the method of Greenwood [15] . The tracer was purified in a Sephadex G-25 fine column (1 × 100 cm) equilibrated with 0.1 M acetic acid containing BSA 0.1% (w/v). The specific activity of the purified labelled peptide was about 600 Ci/mmol. ~ Hippocampal membranes were prepared as previously described by Reubi et al. [37] . Protein concentration was assayed by the method of Lowry et al. [23] , with BSA as a standard. Specific SS binding was measured according to the modified method of Czernik and Petrack [8] . Briefly, the membranes (0.15 mg protein/ml) were incubated in 250 /xl of a medium containing 50 mM Tris-HCl buffer (pH 7.5), 5 mM MgCI 2, 0.2% (w/v) BSA and 0.1 mg/ml bacitracin with 250 pM [~25 i]Tyr ~ ~-SS either in the absence or presence of 0.01-10 nM unlabelled SS. After a 60 min incubation at 30°C, bound and free ligand were separated by centrifugation at 11 000 × g for 2 min and the radioactivity in the resultant pellet was measured. Nonspecific binding was obtained from the amount of radioactivity bound in the presence of 10 -7 M SS and represented about 20% of the binding observed in the absence of unlabelled peptide. This nonspecific component was subtracted from the total bound radioactivity in order to obtain the corresponding specific binding.
Evaluation of radiolabelled peptide degradation
(7.5 mg/ml creatine phosphate and 1 mg/ml creatine kinase), 1 mM IBMX, 0.1 mM PMSF, 1 mg/ml bacitracin, 1 mM EDTA, and test substances (10 -4 M SS or 10 -5 M FK) in 0.1 ml of 0.025 M triethanolamine/HCl buffer (pH 7.4). After a 15 min incubation at 30°C, the reaction was stopped by heating the mixture for 3 min. After cooling, 0.2 ml of an alumina slurry (0.75 g/ml in triethanolamine/HCl buffer, pH 7.4) was added and the suspension was centrifuged. The supernatant was taken for assay of cyclic AMP (cAMP) by the method of Gilman [13] . The SS concentration used was that necessary to achieve inhibition of rat [44] and human [5, 12] brain AC activity. FK was used at a concentration that could effectively stimulate the catalytic subunit of rat AC [44] .
Data analysis
The computer program LIGAND [25] was used to analyze the binding data. The use of this program enabled models of receptors that best fit the given sets of data to be selected. The same program was also used to present the data in the form of Scatchard plots and to compute values for receptor affinity (K d) and density (Bma x) that best fit the sets of binding data for each rat. Statistical comparisons of all the data were carried out with one way analysis of variance (ANOVA) and the Student Newman-Keuls test. Means among groups were considered significantly different when the P value was less than 0.05. Each individual experiment was performed in duplicate.
Results
As shown in Table 1 , SS-mediated inhibition of basal and FK-stimulated AC activity was markedly increased in The inactivation of [125I]TyrH-SS in the incubation medium after exposure to membranes was studied by measuring the ability of preincubated peptide to rebind to fresh membranes [1] . Briefly, [125 I]Tyr1LSS (250 pM) was incubated with membranes from rat hippocampus (0.15 mg protein/ml) for 60 rain at 30°C. After this preincubation, aliquots of the medium were added to fresh membranes and incubated for an additional 60 min at 30°C. The fraction of the added radiolabelled peptide which was specifically bound during the second incubation was measured and expressed as a percentage of the binding that had been obtained in control experiments performed in the absence of membranes during the preincubation period.
Adenylyl cyclase assay
AC activity was measured as previously reported [17] with minor modifications. Briefly, hippocampal membranes (0.06 mg/ml) were incubated with 1.5 mM ATP, 5 mM MgSO4, 10 p.M GTP, an ATP-regenerating system Values represent the mean5-SEM of five separate experiments, each performed in duplicate. In the control group, the results express the mean value of a pool of the control animals. Statistical comparison versus control: " " P < 0.01, " " " P < 0.001. (11) : M) and torskolin (1(1 ' M) ~,n brain adenylatc cyclasc activity (pmol/cAMP/min/mg protein) in hippocampal membranes from control rats (n = 10) and rats pretrcatcd with mepyraminc (30 mg/kg, i.p.) (n=5) or cimetidinc (20 ,ug hippocampal membranes from rats treated with 10.0 /.tg of histamine as compared with control rats. The response of AC to the diterpene forskolin (FK), which is assumed to act directly upon the catalytic subunit of AC, was also examined. The results obtained indicate that the ability of the diterpene to stimulate the enzyme activity was not altered after histamine administration. In addition, no significant differences were observed for the basal and FKstimulated AC activities between control and histaminetreated (0.1, 1.0 or l(I.0 /xg) rats (Table 1) . Pretreatment with the histamine H~ or H: receptor antagonists mepyramine and cimetidine, respectively, also induced an increase in SS-mediated inhibition of basal and FK-stimulated AC activity (Tablc 2).
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Hippocampal G, function, as assessed by inhibiting FK (3 × 10 ~' M)-stimulated AC activity with the stable GTP analog Gpp[NH]p, was similar in control and histamine (10 /,~g)-treated rats (Fig. 1) .
Preliminary experiments confirmed that the specific binding of [~-~51]Tyrll-SS to hippocampal membranes changed linearly with protein concentration and was timedependent in all experimental groups. An apparent equilibrium was observed between 50 and 18(1 min at 30°C (data not shown). All subsequent binding expcriments were therefore conducted at 30°C for 60 min. Hippocampal membranes from all experimental groups showed a similar peptide degradation capacity and the values varied by no more than 10% among the groups. SS binding to hippocampal membranes was found to be markedly increased after histamine administration at a dose of 10.0 /xg as compared with controls (Fig. 2) . This increase was due to a rise in the maximal number of SS receptors (48.2%), as revealed by Scatchard plots of the binding data (Table 3 : Fig. 2 ). In addition, a significant tor antagonists mepyramine and cimetidine, respectively, were administered 1 h before histamine administration. A 29.5% and 27.2% increase in the number of SS receptors accompanied by a 69.6% and 72.7% decrease in their apparent affinity was observed in rats pretreated with mepyramine or cimetidine, respectively ( Table 4 ). The pretreatment with mepyramine and cimetidine administered simultaneously prevented the histamine-induced changes in SS binding to its receptors (Table 4 ). The i.c.v, administration of histamine at a dose of 0.1, 1.0 or 10.0/xg did not significantly affect SSLI content in the hippocampus as compared with the control groups (Table 3) . Table 4 Effect of pretreatment with mepyramine (30 mg/kg, i. 
Discussion
This study demonstrates for the first time that the number of SS receptors and the AC response to SS are increased in the hippocampus of rats treated with 10.0 /.tg of histamine, an effect that is mediated by both H 1 and H 2 histaminergic receptors. The hippocampus was chosen to examine the modulation of the SS receptor/effector system due to the high concentration of SS and its receptors [21, 40] in spite of the moderate density of histaminergic fibers [33, 53] present in this brain area. This moderate density of histaminergic fibers may explain the fact that changes in the somatostatinergic system were only observed at the highest dose tested.
The increased capacity of SS to inhibit basal and FKstimulated AC activity in rats treated with 10.0 /zg of histamine, as compared with the control group, is most likely related to the observed rise in the number of SS receptors. Indeed, the basal and FK-stimulated enzyme activities are not altered by histamine, suggesting that the catalytic subunit of AC is not involved in the increased response to SS. Furthermore, the functional activity of the G i protein was similar in the control and histamine (10.0 /xg)-treated group, which suggests that there is no abnormality in the coupling of the SS receptor to AC.
A relatively high concentration of SS (10 -4 M) was required to produce inhibition of AC activity. This same SS concentration was used by Schettini et al. [44] , Bergstr6m et al. [5] and Garlind et al. [12] in their studies on SS-mediated inhibition of AC activity in the rat and human brain. This concentration is three log units higher than that necessary to displace [125I]Tyr1~-SS binding. A possible explanation for this discrepancy may lie in the observation that G-proteins can modulate the affinity of SS receptors and/or the coupling to the effector system (AC among others). In this respect, Enjalbert et al. [9] and Koch and Schonbrunn [20] have demonstrated that the mobilization of the G-protein by GTP reduces the SS receptor affinity for the neuropeptide in cerebral cortical cells and GH4C ~ pituitary cell clones. Indeed, in the presence of GTP necessary to couple the SS receptor to the AC catalytic subunit, the SS receptor may shift from an apparent high-affinity state (observed in binding studies) to an apparent low-affinity state (observed in AC studies).
The SSLI content and the equilibrium parameters of the SS receptors in the hippocampus of control rats were similar to those previously reported by others [36, 47] . Scatchard analysis of the stoichiometric data suggests the existence of only one type of SS receptor. This finding agrees with some studies in rat brain membranes in which [125I]Tyrlt-SS was also used as a tracer [10, 47] but differs from other reported data where different SS analogs were used [38, 48] . Recently, five different SS receptor subtypes have been cloned [4] and the tissue distribution of the messenger ribonucleic acid for each subtype has been studied in the rat [6, 35] . The fact that this study with
[125I]Tyr~-SS shows only one type of SS receptor might be explained by the hypothesis that this radioligand binds to all types of SS receptors with dissociation constants that are virtually identical and cannot be discriminated by Scatchard analysis.
Overall, the present data are suggestive of a possible role of histamine as a modulator of the SS receptor/effector system in the hippocampus. The molecular mechanism underlying the increase in SS receptors and SS-mediated AC inhibition in hippocampal membranes of histamine (10.0 /xg)-treated rats is unknown. This effect, however, seems to be due to a direct interaction of histamine with histaminergic receptors which are present in high density in this brain area [31, 42] The role of SS receptors in the hippocampus, a structure involved in the regulation of behavior, especially cognitive functions [55] , still remains to be elucidated. However, there are several lines of evidence suggesting that SS can play a physiological role in the modulation of this limbic structure [54] . Since the hippocampus receives histaminergic innervation [33, 53] and SS receptors are modulated by histamine, it is tempting to speculate that in the hippocampus, SS could be involved as a mediator of the effects of histamine on behaviors such as learning and memory. The importance of this observation for basic science and clinical research requires further exploration.
